Developing APX005: humanized mAb CD40 agonist. 3 internally developed programs (1 Ph 2, 2 PC programs) and 8 partnered programs (1 Ph 3, 2 Ph 2, 3 Ph 1, various PC). Dose-escalation study in pts w solid tumors; evaluating APX005 across 8 dosing cohorts + expansion cohort; Dec 2018 exp completion. Add’l Phase 1/2 IST at MDACC assessing APX005M in combi w pembrolizumab in pts w metastatic melanoma. Collab w BMY evaluating APX005M in combo w nivolumab in solid tumors; exp to enroll NSCLC patients who failed prior chemo and melanoma patients who failed prior IO. 8 collaborations in total, incl BMY, Alcon, B. Ingelheim, Janssen, Parker Institute, Neon Tx, Yale Cancer Center, et al. Aug 2018 Series B & C ($73m total) led by Decheng Capital, 3E Bioventures, Virtus Inspire, & SV Tech.
75 Shoreway Road
San Carlos, CA 94070
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.